Clinical Trial Detail

NCT ID NCT02560025
Title Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

acute myeloid leukemia

Therapies

Alisertib

Daunorubicin

Idarubicin

Cytarabine

Age Groups: adult

No variant requirements are available.